Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
ms [2019/07/21 11:49]
sflitman [Multiple Sclerosis]
ms [2020/07/15 00:39] (current)
Line 3: Line 3:
 Multiple sclerosis is a common condition of young people and mature adults, affecting nearly a million Americans.  The most common form is Relapsing-Remitting, but there are also Primary Progressive, Secondary Progressive, and Progressive-Relapsing subtypes.  New trials are directed against the disease itself, hoping to slow progression, or against particular symptoms like spasticity (stiffness of muscles and limbs).   Multiple sclerosis is a common condition of young people and mature adults, affecting nearly a million Americans.  The most common form is Relapsing-Remitting, but there are also Primary Progressive, Secondary Progressive, and Progressive-Relapsing subtypes.  New trials are directed against the disease itself, hoping to slow progression, or against particular symptoms like spasticity (stiffness of muscles and limbs).  
  
-We have no currently enrolling trials for Multiple Sclerosischeck back soon for new opportunities.+New trials are comingplease watch this space 
  
 <html><!-- <html><!--
 +
 ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Active ^ Duration ^ Open Label Extension ^ ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Active ^ Duration ^ Open Label Extension ^
-| Relapsing-Remitting Multiple Sclerosis |  Novel oral agent vs. Tecfidera   III  |  Yes  |  50%  |  11 weeks  |  96 weeks  |+| Relapsing-Remitting Multiple Sclerosis |  Higher dose of approved Ocrevus infusion   III  |  Yes  |  50%  |  11 weeks  |  96 weeks  | 
 +| Primary Progressive Multiple Sclerosis |  Higher dose of approved Ocrevus infusion  |  III  |  Yes  |  50%  |  11 weeks  |  96 weeks  | 
 +| Relapsing-Remitting Multiple Sclerosis |  Oral BKT inhibitor  |  III  |  Yes  |  50%  |  11 weeks  |  96 weeks  | 
 --></html> --></html>
  
Line 20: Line 24:
 <p>  <p> 
 <div align=center>  <div align=center> 
-<form method=post action="http://neurozone.org/cgi-n/emailform.cgi"> +<form method=post action="https://neurozone.org/cgi-n/emailform.cgi"> 
 <input type=hidden name="_site" value="Clinical Research Inquiry">  <input type=hidden name="_site" value="Clinical Research Inquiry"> 
-<input type=hidden name="_link" value="http://neurozone.org/wiki/doku.php?id=ms"> +<input type=hidden name="_link" value="https://neurozone.org/wiki/doku.php?id=ms"> 
 <input type=hidden name=trialtype value="Multiple Sclerosis"> <input type=hidden name=trialtype value="Multiple Sclerosis">
 <table border=2 cellspacing=0 cellpadding=2>  <table border=2 cellspacing=0 cellpadding=2> 
Print/export
QR Code
QR Code ms (generated for current page)